Prognostic value of the Hospital Frailty Risk Score (HFRS) and outcomes in peripheral artery disease and end-stage kidney disease.

IF 3.3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Vascular Medicine Pub Date : 2025-04-01 Epub Date: 2025-03-13 DOI:10.1177/1358863X251316837
Monil Majmundar, Chan Wan-Chi, Kunal N Patel, Vidit Majmundar, Rhythm Vasudeva, Kirk A Hance, Adam Ali, George Hajj, Axel Thors, Jinxiang Hu, Kamal Gupta
{"title":"Prognostic value of the Hospital Frailty Risk Score (HFRS) and outcomes in peripheral artery disease and end-stage kidney disease.","authors":"Monil Majmundar, Chan Wan-Chi, Kunal N Patel, Vidit Majmundar, Rhythm Vasudeva, Kirk A Hance, Adam Ali, George Hajj, Axel Thors, Jinxiang Hu, Kamal Gupta","doi":"10.1177/1358863X251316837","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Peripheral artery disease (PAD) and end-stage kidney disease (ESKD) are independent risk factors affecting outcomes like in-hospital mortality. The role of a frailty index in prognosticating outcomes in patients with ESKD and PAD is unknown. We aim to assess the prognostic value of the Hospital Frailty Risk Score (HFRS) and its association with outcomes in these patients.</p><p><strong>Methods: </strong>We identified patients with PAD using data from the United States Renal Data System (USRDS) for the years 2015-2018. These patients were stratified into three categories of frailty risk based on their HFRS, a validated frailty assessment tool using ICD-10 codes: low (< 5), intermediate (5-10), and high risk (> 10) and based on revascularization or not. Primary outcomes included in-hospital mortality and composite of mortality or major amputation. Secondary outcomes encompassed postdischarge mortality and composite of mortality or major amputation at 1 year.</p><p><strong>Results: </strong>Out of 122,649 patients with PAD and ESKD, 4118 underwent revascularization and 118,531 did not. In-hospital outcomes demonstrated a nonlinear relationship and postdischarge outcomes displayed a nearly linear relationship with HFRS, regardless of revascularization status. In both cohorts, the high-risk group was associated with a significantly higher risk of in-hospital mortality/amputation (revascularization: odds ratio [OR] 4.6, 95% CI 3.3-6.2, <i>p</i> < 0.001; no revascularization: OR 3.1, 95% CI 2.8-3.3, <i>p</i> < 0.001) and mortality (revascularization: OR 5.5, 95% CI 3.4-8.7, <i>p</i> < 0.001; no revascularization: OR 5.1, 95% CI 4.6-5.6, <i>p</i> < 0.001) compared with the low-risk group.</p><p><strong>Conclusion: </strong>In patients with ESKD and PAD, the HFRS serves as a valuable predictor of mortality and amputation irrespective of revascularization. This information can support informed decision-making.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"138-146"},"PeriodicalIF":3.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1358863X251316837","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Peripheral artery disease (PAD) and end-stage kidney disease (ESKD) are independent risk factors affecting outcomes like in-hospital mortality. The role of a frailty index in prognosticating outcomes in patients with ESKD and PAD is unknown. We aim to assess the prognostic value of the Hospital Frailty Risk Score (HFRS) and its association with outcomes in these patients.

Methods: We identified patients with PAD using data from the United States Renal Data System (USRDS) for the years 2015-2018. These patients were stratified into three categories of frailty risk based on their HFRS, a validated frailty assessment tool using ICD-10 codes: low (< 5), intermediate (5-10), and high risk (> 10) and based on revascularization or not. Primary outcomes included in-hospital mortality and composite of mortality or major amputation. Secondary outcomes encompassed postdischarge mortality and composite of mortality or major amputation at 1 year.

Results: Out of 122,649 patients with PAD and ESKD, 4118 underwent revascularization and 118,531 did not. In-hospital outcomes demonstrated a nonlinear relationship and postdischarge outcomes displayed a nearly linear relationship with HFRS, regardless of revascularization status. In both cohorts, the high-risk group was associated with a significantly higher risk of in-hospital mortality/amputation (revascularization: odds ratio [OR] 4.6, 95% CI 3.3-6.2, p < 0.001; no revascularization: OR 3.1, 95% CI 2.8-3.3, p < 0.001) and mortality (revascularization: OR 5.5, 95% CI 3.4-8.7, p < 0.001; no revascularization: OR 5.1, 95% CI 4.6-5.6, p < 0.001) compared with the low-risk group.

Conclusion: In patients with ESKD and PAD, the HFRS serves as a valuable predictor of mortality and amputation irrespective of revascularization. This information can support informed decision-making.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
医院衰弱风险评分(HFRS)在外周动脉疾病和终末期肾脏疾病的预后价值
背景:外周动脉疾病(PAD)和终末期肾脏疾病(ESKD)是影响院内死亡率等结局的独立危险因素。虚弱指数在ESKD和PAD患者预后中的作用尚不清楚。我们的目的是评估医院虚弱风险评分(HFRS)的预后价值及其与这些患者预后的关系。方法:我们使用美国肾脏数据系统(USRDS) 2015-2018年的数据识别PAD患者。这些患者根据其HFRS(一种使用ICD-10代码验证的衰弱评估工具)分为三类:低(< 5)、中(5-10)和高风险(bbb10),并基于是否有血运重建。主要结局包括住院死亡率和综合死亡率或主要截肢。次要结局包括出院后死亡率和1年内死亡率或主要截肢的综合。结果:在122,649例PAD和ESKD患者中,4118例接受了血运重建术,118,531例没有。无论血运重建状况如何,住院预后与HFRS呈非线性关系,出院后预后与HFRS呈近线性关系。在两个队列中,高危组与住院死亡率/截肢的风险显著升高相关(血运重建术:优势比[OR] 4.6, 95% CI 3.3-6.2, p < 0.001;无血运重建:OR 3.1, 95% CI 2.8-3.3, p < 0.001)和死亡率(血运重建:OR 5.5, 95% CI 3.4-8.7, p < 0.001;无血运重建术:OR为5.1,95% CI为4.6-5.6,p < 0.001)。结论:在ESKD和PAD患者中,无论血运重建与否,HFRS都可以作为死亡率和截肢的有价值的预测指标。这些信息可以支持明智的决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Vascular Medicine
Vascular Medicine 医学-外周血管病
CiteScore
5.70
自引率
5.70%
发文量
158
审稿时长
>12 weeks
期刊介绍: The premier, ISI-ranked journal of vascular medicine. Integrates the latest research in vascular biology with advancements for the practice of vascular medicine and vascular surgery. It features original research and reviews on vascular biology, epidemiology, diagnosis, medical treatment and interventions for vascular disease. A member of the Committee on Publication Ethics (COPE)
期刊最新文献
Images in Vascular Medicine: Percutaneous microwave ablation of a massive high-flow upper limb arteriovenous malformation. Pelvic venous disease: A frontier of possibility. Plethysmography compared to ultrasound for the evaluation of chronic venous insufficiency. Vorapaxar utilization and cost trends in US public insurance programs. Impact of lipid-rich plaques in the femoropopliteal artery on limb outcomes in patients undergoing endovascular therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1